P
PurePeptides
Request Full Data Access to the Medutest database of peptide tests.
Products examined
| Product | Rating | Samples | Avg | Min | Max | Latest |
|---|---|---|---|---|---|---|
| Retatrutide | A | 5 | 7.7 | 6.8 | 9.4 | 27 Feb 2025 |
| Tirzepatide | B | 6 | 7.0 | 6.6 | 7.8 | 27 Feb 2025 |
| Ipamorelin | E | 4 | 3.6 | 3.5 | 3.7 | 27 Feb 2025 |
| Alprostadil | X | 1 | 6.6 | 6.6 | 6.6 | 6 May 2025 |
| ANPP (4-anilino-N-phenethylpiperidine) CAS 21409-26-7 | X | 1 | 4.0 | 2.7 | 2.7 | 3 Jul 2025 |
| AOD9604 | X | 1 | 5.2 | 5.2 | 5.2 | 2 Jul 2025 |
| Arimidex (Anastrozole) | X | 1 | 4.9 | 4.9 | 4.9 | 17 Dec 2024 |
| Benzaldehyde CAS 100-52-7 | X | 1 | 5.0 | 5.0 | 5.0 | 6 May 2025 |
| Blend 500 (Tren E/Mast E) | X | 1 | 6.9 | 6.9 | 6.9 | 2 Jul 2025 |
| BPC157 10mg + TB500 10mg Blend | X | 1 | 5.6 | 5.6 | 5.6 | 27 Feb 2025 |
| Chonluten | X | 1 | 6.2 | 6.2 | 6.2 | 8 Jul 2025 |
| Clomid | X | 1 | 6.5 | 6.5 | 6.5 | 6 May 2025 |
| GLOW GHK-CU 50mg+TB500 10mg+BPC157 10mg | X | 1 | 5.5 | 5.5 | 5.5 | 16 Mar 2025 |
| Halotestin (Fluoxymesterone) | X | 1 | 6.3 | 6.3 | 6.3 | 9 Jun 2025 |
| HGH Fragment 176-191 | X | 1 | 5.6 | 5.6 | 5.6 | 24 Apr 2025 |
| HMG | X | 1 | 9.6 | 9.6 | 9.6 | 14 Jan 2025 |
| Humanin | X | 1 | 4.0 | 4.0 | 4.0 | 2 Jul 2025 |
| KLOW GHK-CU 50mg+TB500 10mg+BPC157 10mg+KPV 10mg | X | 1 | 4.0 | 3.8 | 3.8 | 25 Apr 2025 |
| KPV Oral | X | 1 | 5.4 | 5.4 | 5.4 | 13 Jun 2025 |
| MT-1 | X | 1 | 9.0 | 9.0 | 9.0 | 17 Dec 2024 |
| Ostarine (MK-2866) | X | 1 | 5.0 | 5.0 | 5.0 | 14 Jan 2025 |
| P21 | X | 1 | 5.7 | 5.7 | 5.7 | 17 Dec 2024 |
| P2NP (1-phenyl-2-nitropropene) CAS 705-60-2 | X | 1 | 4.0 | 2.8 | 2.8 | 11 Jun 2025 |
| Pancragen | X | 1 | 5.6 | 5.6 | 5.6 | 28 Mar 2025 |
| PE 22-28 | X | 1 | 8.7 | 8.7 | 8.7 | 11 Jun 2025 |
| Primobolan E | X | 1 | 4.4 | 4.4 | 4.4 | 27 Feb 2025 |
| Retatrutide 30mg Pen Kit | X | 1 | 5.2 | 5.2 | 5.2 | 27 Feb 2025 |
| Semaglutide Oral | X | 1 | 5.0 | 5.0 | 5.0 | 16 Mar 2025 |
| SNAP-8 | X | 1 | 6.3 | 6.3 | 6.3 | 28 Mar 2025 |
| SR9009 | X | 1 | 6.1 | 6.1 | 6.1 | 13 Jun 2025 |
| Superdrol | X | 1 | 7.2 | 7.2 | 7.2 | 28 Mar 2025 |
| Sustanon 250 | X | 1 | 7.6 | 7.6 | 7.6 | 2 Jul 2025 |
| T3 (Liothyronine) | X | 1 | 6.1 | 6.1 | 6.1 | 2 Jul 2025 |
| Test Enanthate | X | 1 | 7.0 | 7.0 | 7.0 | 13 Feb 2025 |
| Testo 600 (Test Acetate 180mg+TPP 220mg+Cyp 200mg) | X | 1 | 5.8 | 5.8 | 5.8 | 14 Jan 2025 |
The certificates
| Date | Product | Score | Declared | Measured | Deviation | Purity | Laboratory |
|---|---|---|---|---|---|---|---|
| 24 May 2026 | HGH Fragment 176-191 | 6.5 | 2mg | 2.2mg | +8.3% | 97.21% | Lab E |
| 24 May 2026 | Humanin | 4.2 | 50mg | 45.4mg | -9.1% | 96.02% | Lab D |
| 24 May 2026 | P21 | 4.0 | 10mg | 10.8mg | +7.7% | 96.02% | Lab D |
| 24 May 2026 | Pancragen | 4.5 | 15mg | 18.7mg | +24.3% | 98.05% | Lab B |
| 24 May 2026 | Primobolan E | 4.5 | 300mg/ml | 342.3mg/ml | +14.1% | 99.93% | Lab A |
| 24 May 2026 | SR9009 | 5.5 | 10mg | 12.1mg | +20.5% | 97.46% | Lab G |
| 23 May 2026 | Semaglutide Oral | 6.6 | 10mg | 10.5mg | +5.1% | 95.60% | Lab E |
| 23 May 2026 | Test Enanthate | 6.2 | 100mg/ml | 123.2mg/ml | +23.2% | 97.49% | Lab E |
| 21 May 2026 | Alprostadil | 5.6 | 20mg | 20.2mg | +0.9% | 98.32% | Lab A |
| 21 May 2026 | KLOW GHK-CU 50mg+TB500 10mg+BPC157 10mg+KPV 10mg | 4.0 | 50mg | 48.2mg | -3.7% | 97.86% | Lab G |
| 20 May 2026 | Blend 500 (Tren E/Mast E) | 7.8 | 300mg/ml | 319.8mg/ml | +6.6% | 99.01% | Lab F |
| 20 May 2026 | KPV Oral | 6.5 | 100mg | 114.7mg | +14.7% | 99.70% | Lab G |
| 29 Jan 2026 | Retatrutide 30mg Pen Kit | 4.6 | 5mg | 4.9mg | -2.9% | 96.87% | Lab G |
| 26 Jan 2026 | Testo 600 (Test Acetate 180mg+TPP 220mg+Cyp 200mg) | 7.3 | 100mg/ml | 89.2mg/ml | -10.8% | 96.26% | Lab C |
| 19 Jan 2026 | Retatrutide | 7.5 | 5mg | 5.1mgwebsite | 5.63mg | +10.2% | RT5314 |
| 19 Jan 2026 | SNAP-8 | 5.0 | 5mg | 5.2mg | +3.2% | 95.69% | Lab B |
| 9 Jan 2026 | ANPP (4-anilino-N-phenethylpiperidine) CAS 21409-26-7 | 4.0 | 500g | 548.3g | +9.7% | 97.99% | Lab F |
| 9 Jan 2026 | Halotestin (Fluoxymesterone) | 4.0 | 25mg | 24.5mg | -1.9% | 95.50% | Lab D |
| 9 Jan 2026 | Superdrol | 8.1 | 25mg | 22.0mg | -12.0% | 95.89% | Lab G |
| 7 Jan 2026 | Ostarine (MK-2866) | 4.0 | 25mg | 26.8mg | +7.0% | 97.51% | Lab A |
| 6 Jan 2026 | Sustanon 250 | 9.2 | 200mg/ml | 211.5mg/ml | +5.8% | 97.66% | Lab G |
| 29 Dec 2025 | Benzaldehyde CAS 100-52-7 | 5.7 | 1g | 1.0g | +2.1% | 99.97% | Lab C |
| 29 Dec 2025 | BPC157 10mg + TB500 10mg Blend | 7.0 | 10mg | 12.2mg | +22.0% | 96.98% | Lab A |
| 29 Dec 2025 | Chonluten | 7.6 | 30mg | 32.2mg | +7.4% | 95.72% | Lab D |
| 29 Dec 2025 | T3 (Liothyronine) | 6.7 | 20mg | 24.6mg | +23.0% | 96.45% | Lab A |
| 12 Dec 2025 | PE 22-28 | 7.3 | 50mg | 62.0mg | +24.0% | 98.91% | Lab E |
| 5 Dec 2025 | MT-1 | 9.4 | 2mg | 2.0mg | -1.9% | 97.79% | Lab A |
| 23 Nov 2025 | Clomid | 6.5 | 10mg | 9.3mg | -7.2% | 99.77% | Lab E |
| 14 Nov 2025 | GLOW GHK-CU 50mg+TB500 10mg+BPC157 10mg | 6.2 | 2mg | 1.8mg | -8.9% | 99.51% | Lab G |
| 5 Nov 2025 | Arimidex (Anastrozole) | 5.9 | 20mg | 22.5mg | +12.5% | 95.62% | Lab F |
| 5 Nov 2025 | P2NP (1-phenyl-2-nitropropene) CAS 705-60-2 | 4.0 | 10g | 8.5g | -14.7% | 98.70% | Lab E |
| 9 Oct 2025 | HMG | 10.0 | 30mg | 30.5mg | +1.8% | 96.07% | Lab F |
| 3 Oct 2025 | AOD9604 | 6.2 | 20mg | 18.8mg | -6.0% | 99.75% | Lab A |
| 4 Sep 2025 | Tirzepatide | 7.3 | 30mg | (no batch claim) | 28.1mg | -6.3% | (no batch ID) |
| 11 Aug 2025 | Tirzepatide | 6.6 | 60mg | (no batch claim) | 65.7mg | +9.5% | (no batch ID) |
| 20 Mar 2025 | Retatrutide | 7.2 | 10mg | (no batch claim) | 11.86mg | +18.6% | 2024-10-21 |
| 20 Mar 2025 | Ipamorelin | 3.7 | 2mg | (no batch claim) | 1.44mg | -28.0% | 2024-01-05 |
| 20 Mar 2025 | Tirzepatide | 7.8 | 10mg | (no batch claim) | 11.4mg | +14.0% | 2024-07-23 |